EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+3.74%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$2.09B
AUM Growth
+$101M
(+5.1%)
Cap. Flow
+$51.3M
Cap. Flow
% of AUM
2.45%
Top 10 Holdings %
Top 10 Hldgs %
52.15%
Holding
437
New
42
Increased
236
Reduced
93
Closed
39
Top Buys
| 1 |
Apple
AAPL
|
$22.7M |
| 2 |
Microsoft
MSFT
|
$17M |
| 3 |
NVIDIA
NVDA
|
$15.1M |
| 4 |
Amazon
AMZN
|
$13.7M |
| 5 |
Meta Platforms (Facebook)
META
|
$13.3M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$95M |
| 2 |
KE Holdings
BEKE
|
$15.8M |
| 3 |
Full Truck Alliance
YMM
|
$10.2M |
| 4 |
Tencent Music
TME
|
$10M |
| 5 |
TSMC
TSM
|
$8.26M |
Sector Composition
| 1 | Technology | 37.79% |
| 2 | Consumer Discretionary | 26.64% |
| 3 | Communication Services | 10.64% |
| 4 | Healthcare | 6.89% |
| 5 | Financials | 6.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
MannKind Corp
MNKD
$1.64B
| $124K | 0.01% |
24,667
+2,628
| +12% | +$13.2K |
|
377
Nurix Therapeutics
NRIX
$697M
| $122K | 0.01% |
+10,288
| New | +$122K |
|
378
Myriad Genetics
MYGN
$632M
| $122K | 0.01% |
13,720
+1,968
| +17% | +$17.5K |
|
379
Intellia Therapeutics
NTLA
$1.25B
| $120K | 0.01% |
16,831
-1,222
| -7% | -$8.69K |
|
380
Vir Biotechnology
VIR
$714M
| $104K | 0.01% |
+15,993
| New | +$104K |
|
381
Ford
F
$46.5B
| $102K | ﹤0.01% |
10,208
| – | – |
|
382
Anavex Life Sciences
AVXL
$804M
| $102K | ﹤0.01% |
+11,911
| New | +$102K |
|
383
Rocket Pharmaceuticals
RCKT
$349M
| $97.2K | ﹤0.01% |
14,567
+3,513
| +32% | +$23.4K |
|
384
Cogent Biosciences
COGT
$1.81B
| $93.9K | ﹤0.01% |
15,670
+4,290
| +38% | +$25.7K |
|
385
89bio
ETNB
$1.28B
| $93.3K | ﹤0.01% |
+12,827
| New | +$93.3K |
|
386
ImmunityBio
IBRX
$2.26B
| $91.3K | ﹤0.01% |
30,331
-8,569
| -22% | -$25.8K |
|
387
Day One Biopharmaceuticals
DAWN
$759M
| $88.3K | ﹤0.01% |
11,136
-140
| -1% | -$1.11K |
|
388
Arcus Biosciences
RCUS
$1.23B
| $82.4K | ﹤0.01% |
+10,498
| New | +$82.4K |
|
389
Kura Oncology
KURA
$706M
| $80.9K | ﹤0.01% |
12,252
+1,951
| +19% | +$12.9K |
|
390
Cheche Group
CCG
$95.4M
| $70.5K | ﹤0.01% |
+83,069
| New | +$70.5K |
|
391
Altimmune
ALT
$314M
| $67.1K | ﹤0.01% |
13,427
+2,268
| +20% | +$11.3K |
|
392
Emergent Biosolutions
EBS
$407M
| $50.5K | ﹤0.01% |
10,383
+145
| +1% | +$705 |
|
393
Relay Therapeutics
RLAY
$690M
| $50.2K | ﹤0.01% |
19,165
+1,511
| +9% | +$3.96K |
|
|
VERV
394
DELISTED
Verve Therapeutics
VERV
| $48.1K | ﹤0.01% |
+10,522
| New | +$48.1K |
|
395
Akebia Therapeutics
AKBA
$801M
| $37.1K | ﹤0.01% |
19,311
+6,595
| +52% | +$12.7K |
|
396
Sana Biotechnology
SANA
$757M
| $30.6K | ﹤0.01% |
18,236
-3,966
| -18% | -$6.66K |
|
397
Humacyte
HUMA
$231M
| $29.2K | ﹤0.01% |
17,133
+788
| +5% | +$1.34K |
|
398
Scilex Holding
SCLX
$142M
| $7.81K | ﹤0.01% |
898
| – | – |
|
399
Erasca
ERAS
$420M
| – | – |
-14,838
| Closed | -$37.2K |
|
400
iShares MSCI Japan ETF
EWJ
$15.4B
| – | – |
-3,602
| Closed | -$242K |
|